Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2020
Pharma News, 2020
WuXi Biologics and Bayer Enter into an Acquisition Agreement on a Drug Product Plant in Germany
SHANGHAI and LEVERKUSEN, Germany, January 16, 2020 –WuXi Biologics (“WuXi Bio”) (2269.
German drug assessment body not convinced by Bayer's cancer drug Vitrakvi
FRANKFURT (Reuters) - Germany’s drug assessment body said that data provided by Bayer on its precision cancer drug Vitrakvi did not provide clear enough evidence of benefits, in a setback to...
Nektar withdraws application for opioid painkiller after FDA panel's vote
(Reuters) - Nektar Therapeutics said on Tuesday it was withdrawing the application for its opioid painkiller for adults with chronic low back pain, after a U.
Here's Why Rigel Pharmaceuticals Is Erupting This Week
The pharmaceutical stock is surging after providing preliminary results for the fourth quarter of 2019.
Horizon enlists Mammoth in CRISPR move
Horizon Discovery has announced a new collaboration and license agreement with Mammoth Biosciences, in order to access the company’s novel CRISPR platform and facilitate a new generation of genetica...
Cyber attacks hit more than half of healthcare orgs in last year
A new report has revealed that last year in the UK, 67% of healthcare organisations experienced a cyber security incident.
UK cell and gene clinical trials up 45% from 2018
The Cell and Gene Therapy Catapult (CGT Catapult) has revealed that there are currently 127 ongoing cell and gene trials in the UK, representing a ~45% increase compared to 2018, and accou...
Swinging for the Fences: Alexion to Test Ultomiris in ALS
Alexion Pharmaceuticals announced at the JP Morgan Healthcare Conference that it was planning to initiate a pivotal Phase III trial of Ultomiris (ravulizumab) in amyotrophic lateral sclerosis ...
Phase III STRENGTH trial for Epanova in mixed dyslipidaemia will close
On recommendations by an independent committee, AstraZeneca will close its STRENGTH trial for Epanova, which has shown low likelihood of being beneficial to patients with mixed dyslipidaemia.
Governor of California proposes state-run drug label
In a bid to lower the costs of medicines, California’s governor has suggested contracting generic drug manufacturers to make pharmaceutical products for the state to sell, according to reports.
China pneumonia outbreak not spreading at present: WHO
LONDON/BEIJING (Reuters) - An outbreak of pneumonia that has killed one person in China and infected 40 others appears to be linked to a single seafood market in the central city of Wuhan and ...
Eli Lilly to launch half-priced versions of two more insulin products
(Reuters) - Eli Lilly and Co said on Tuesday it plans to sell two versions of insulin products at half their current U.
69
70
71
72
73
74
75
76
